The use of diversity profiling to characterize chemical modulators of the histone deacetylases

被引:74
作者
Blackwell, Leonard [1 ]
Norris, Jacqueline [1 ]
Suto, Carla M. [1 ]
Janzen, William P. [1 ]
机构
[1] Amphora Discovery Corp, Durham, NC 27713 USA
关键词
HDAC; polyphenol; microfluidics; profiling; hydroxamate;
D O I
10.1016/j.lfs.2008.03.004
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Target specificity and off-target liabilities are routinely monitored during the early phases of drug discovery for most kinase projects. Typically these criteria are evaluated using a profiling panel comprised of a diverse collection of in vitro kinase assays and relates compound structure to potency and selectivity. The success of these efforts has led to the design of similar panels for phosphatase, protease, and epigenetic targets. Here the implementation of an epigenetic profiling panel, comprised of eleven histone deacetylases (HDACs) and one histone acetyltransferase (HAT), was used to evaluate chemical modulators of these enzymes. HDAC inhibitors (HDACi) such as sodium butyrate and trichostatin A demonstrate diverse biological effects which have led to broad speculation about their therapeutic potential in multiple disease states. Some HDAG have demonstrated tumor suppression in vivo and recently Zolinza was the first HDAG approved by the FDA for the treatment of cutaneous T-cell lymphoma. While HDACi have demonstrated therapeutic utility, many of the first generation compounds are pan-inhibitors. Thus, use of an HDAC profiling panel will be essential in achieving isoform specificity of the next generation of inhibitors. To this end, twenty-one compounds, twelve of which are known to have activities against the HDACs, were tested to evaluate the utility of the epigenetic panel. Additionally, these compounds were tested against a larger 72 member enzyme panel comprised of kinase, phosphatase and protease activities. This effort represents the first time these compounds have been profiled with such a broad range of biochemical activities. (c) 2008 Elsevier Inc. All rights reserved.
引用
收藏
页码:1050 / 1058
页数:9
相关论文
共 54 条
[1]   Identification of a small molecule inhibitor of Sir2p [J].
Bedalov, A ;
Gatbonton, T ;
Irvine, WP ;
Gottschling, DE ;
Simon, JA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (26) :15113-15118
[2]   Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies [J].
Bhalla, KN .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (17) :3971-3993
[3]   Anticancer activities of histone deacetylase inhibitors [J].
Bolden, Jessica E. ;
Peart, Melissa J. ;
Johnstone, Ricky W. .
NATURE REVIEWS DRUG DISCOVERY, 2006, 5 (09) :769-784
[4]   Substrate specificity and kinetic mechanism of the Sir2 family of NAD+-dependent histone/protein deacetylases [J].
Borra, MT ;
Langer, MR ;
Slama, JT ;
Denu, JM .
BIOCHEMISTRY, 2004, 43 (30) :9877-9887
[5]   Histone deacetylase inhibitors: gathering pace [J].
Carey, Nessa ;
La Thangue, Nicholas B. .
CURRENT OPINION IN PHARMACOLOGY, 2006, 6 (04) :369-375
[6]   Design, synthesis, and evaluation of benzothiadiazepine hydroxamates as selective tumor necrosis factor-α converting enzyme inhibitors [J].
Cherney, RJ ;
Duan, JJW ;
Voss, ME ;
Chen, LH ;
Wang, L ;
Meyer, DT ;
Wasserman, ZR ;
Hardman, KD ;
Liu, RQ ;
Covington, MB ;
Qian, MX ;
Mandlekar, S ;
Christ, DD ;
Trzaskos, JM ;
Newton, RC ;
Magolda, RL ;
Wexler, RR ;
Decicco, CP .
JOURNAL OF MEDICINAL CHEMISTRY, 2003, 46 (10) :1811-1823
[7]  
Colletti SL, 2001, BIOORG MED CHEM LETT, V11, P107, DOI 10.1016/S0960-894X(00)00604-1
[8]   A small molecule-kinase interaction map for clinical kinase inhibitors [J].
Fabian, MA ;
Biggs, WH ;
Treiber, DK ;
Atteridge, CE ;
Azimioara, MD ;
Benedetti, MG ;
Carter, TA ;
Ciceri, P ;
Edeen, PT ;
Floyd, M ;
Ford, JM ;
Galvin, M ;
Gerlach, JL ;
Grotzfeld, RM ;
Herrgard, S ;
Insko, DE ;
Insko, MA ;
Lai, AG ;
Lélias, JM ;
Mehta, SA ;
Milanov, ZV ;
Velasco, AM ;
Wodicka, LM ;
Patel, HK ;
Zarrinkar, PP ;
Lockhart, DJ .
NATURE BIOTECHNOLOGY, 2005, 23 (03) :329-336
[9]   Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors [J].
Finnin M.S. ;
Donigian J.R. ;
Cohen A. ;
Richon V.M. ;
Rifkind R.A. ;
Marks P.A. ;
Breslow R. ;
Pavletich N.P. .
Nature, 1999, 401 (6749) :188-193
[10]   Human HDAC7 histone deacetylase activity is associated with HDAC3 in vivo [J].
Fischle, W ;
Dequiedt, F ;
Fillion, M ;
Hendzel, MJ ;
Voelter, W ;
Verdin, E .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (38) :35826-35835